NeOnc's Intranasal NEO100 Hits Primary Endpoint in Recurrent Glioma Trial
Event summary
- NeOnc's Phase 2a trial of intranasal NEO100 met primary endpoint with 6-month PFS of 48.9% vs. 20% benchmark (p=0.0047).
- Median overall survival reached 26.09 months; 86.7% of patients alive at six months.
- No major toxicities reported; five of 24 patients remain on treatment, including one partial response ongoing beyond 114 days.
- Company plans Type B meeting with FDA to align on registrational path for recurrent IDH1-mutant high-grade glioma.
The big picture
NeOnc's results represent a potential breakthrough in treating recurrent high-grade glioma, an area with no approved targeted therapies. The intranasal delivery approach bypasses systemic toxicities while achieving meaningful survival outcomes. This positions NEO100 as a potential first-in-class option if confirmatory data supports the Phase 2a findings.
What we're watching
- Regulatory Pathway
- Whether FDA will accept the proposed registrational strategy for a population with no approved targeted therapies.
- Clinical Validation
- How durable responses and survival metrics hold up in larger, controlled studies given small sample size limitations.
- Competitive Positioning
- The pace at which NeOnc can differentiate NEO100 from existing IDH-targeted therapies focused on frontline lower-grade glioma.